Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) was Reiterated by Mizuho to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 195 from a previous price target of $193 . Mizuho advised their investors in a research report released on Jul 19, 2016.
Many Wall Street Analysts have commented on Jazz Pharmaceuticals plc – Ordinary Shares. Goldman Initiated Jazz Pharmaceuticals plc – Ordinary Shares on Jun 6, 2016 to “Buy”, Price Target of the shares are set at $196.Company shares were Upgraded by Mizuho on May 11, 2016 to ” Buy”, Firm has raised the Price Target to $ 193 from a previous price target of $137 .Company shares were Reiterated by UBS on May 11, 2016 to “Buy”, Firm has raised the Price Target to $ 168 from a previous price target of $162 .
On the company’s financial health, Jazz Pharmaceuticals plc – Ordinary Shares reported $2.26 EPS for the quarter, missing the analyst consensus estimate by $ -0.06 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $2.32. The company had revenue of $336.01 million for the quarter, compared to analysts expectations of $340.17 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.
Jazz Pharmaceuticals plc – Ordinary Shares closed down -0.05 points or -0.04% at $142.38 with 3,06,368 shares getting traded on Friday. Post opening the session at $142.43, the shares hit an intraday low of $141.76 and an intraday high of $143.96 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jul 18, 2016, Michael Patrick Miller (SVP, US Commercial) sold 100 shares at $142.43 per share price. According to the SEC, on Jul 13, 2016, Karen L. Smith (Global Head of R&D and CMO) purchased 580 shares at $143.63 per share price. On May 26, 2016, Seamus Mulligan (director) sold 27,968 shares at $150.13 per share price, according to the Form-4 filing with the securities and exchange commission.